Skip to content

Prostate-Specific Antigen to Creatinine Ratio, Urine

Published: August 9, 2026Updated: August 16, 2026

A urine test that measures prostate-specific antigen relative to urine creatinine, helping assess prostate-related conditions when a blood PSA test is unsuitable.

Quick summary

["This test may help evaluate possible prostate disease, but an abnormal result requires clinical review and confirmatory testing."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
48167-1
Short code
PSA/Creat Ur
Synonyms
PSA/Creat Ur
Category
kidney
Sample
urine
Container
Sterile urine container
Units
N/A
Ref low
0
Ref high
4
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
CPT
84153
SNOMED
39392002
Specimen volume
10 mL
Stability
Room temperature: 2h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
0
Lipemia max
0
Icterus max
0
TAT
4–24 hours
Order
routine

What is this test?

This test measures prostate-specific antigen (PSA) in urine and compares it with the amount of creatinine in the same sample. Creatinine is used to account for differences in urine concentration.

Why might I need this test?

It may be used as an additional way to assess the prostate when a blood PSA test cannot be used or when the healthcare professional is evaluating symptoms that could be related to prostate disease. It does not replace other clinical evaluations.

How is the test performed?

A urine sample is collected and tested to determine the amounts of PSA and creatinine. The laboratory then calculates the PSA-to-creatinine ratio and sends the result to your healthcare professional.

How do I prepare for the test?

No special preparation is usually required for a spot urine sample, but follow the collection instructions provided by the laboratory. Tell your clinician about a recent urinary infection, prostate procedure, or symptoms such as painful urination, which may affect interpretation.

Reference range

Normal: <4.0 ng/mLN/A

Specimen: urine

No special preparation required. For PSA, avoid sexual activity for 24-48 hours before the test.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

A higher-than-expected ratio may occur with benign prostate enlargement, prostatitis or urinary infection, and sometimes prostate cancer. A lower ratio can occur for several reasons, including variation in urine concentration. The result must be interpreted with symptoms, examination findings, and other tests because it is not diagnostic by itself.

Short name

Urine PSA/Creatinine Ratio

Frequently asked questions

Is this the same as a blood PSA test?
No. This test uses urine, while a standard PSA test measures PSA in blood. The urine result is reported as a ratio to urine creatinine.
Does a high ratio mean I have prostate cancer?
No. A high ratio can result from benign prostate enlargement, infection, inflammation, or other factors. Additional testing may be needed to determine the cause.
Does the urine PSA ratio replace other prostate evaluations?
No. Your clinician may also review your symptoms, perform a prostate examination, and use blood tests, imaging, or biopsy when appropriate.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy